Clinuvel Pharmaceuticals (OTCPK:CLVL.Y) Earnings Call Presentation

Financial Performance & Growth - CLINUVEL achieved its 9th consecutive annual profit in FY2025[12] - Total revenues, interest, and other income reached A$105.3 million (US$70 million), a 10% increase[13] - Cash reserves increased by 22% to A$224.1 million (US$148 million)[13] - The company reinvests approximately 40% of its profits into RD&I[15] - Net profit margin is 34%[15] Product Pipeline & Market - SCENESSE® is commercially available for adult EPP in multiple regions[8] - CLINUVEL is expanding SCENESSE® to treat adolescent EPP and vitiligo[8] - The total addressable market (TAM) for vitiligo is estimated at US$4.5 billion[10] - The company is pursuing M&A opportunities targeting pharmaceutical and PhotoCosmetic products[11] U.S. Expansion - American revenues now account for over 50% of total revenue[3] - The company is planning a Nasdaq uplisting of its ADRs (Level 2) with an SEC filing expected in Q4[3]